Predictive factors for nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD)

Journal of Gastrointestinal and Liver Diseases

Volumn 20, Issue 2, 2011, Pages 153-159

  Fierbinteanu Braticevici, Carmen ^a   Baicus, Cristian ^b   Tribus, Laura ^a   Papacocea, Raluca ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Carol Davila School of Medicine   (Romania)

Author keywords

Fibrosis; Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Predictive factors

Indexed keywords

ALBUMIN; AMINOTRANSFERASE; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; INSULIN; LIPID;

ADULT; AGED; ALBUMIN BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; BODY MASS; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INTERNATIONAL NORMALIZED RATIO; LIPID ANALYSIS; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATIENT IDENTIFICATION; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; ULTRASOUND;

ADULT; AGED; BIOPSY; BODY MASS INDEX; FATTY LIVER; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 79960088640     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Ludwig J, Viggiano TR, McGill DB. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.
2. Adams LA, Feldstein AE. Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis. J Dig Dis 2011; 12: 10-16.
3. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109:433-438.
4. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94:2467-2474.
5. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313-1321.
6. Ratziu V, Poynard T. Nonalcoholic fatty liver disease: 30 years research changed NASH. Gastroenterol Clin Biol 2009; 33:850-808.
7. Ratziu V, Bellentani, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatology 2010; 53: 372-384.
8. Tarantino G, Saldalamacchia G, Conca P, Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol 2007;22:293-303.
9. Singh DK, Sakhuja P, Malhotra V, Gondal R, Sarin SK. Independent predictors of steatohepatitis and fibrosis in asian indian patients with non-alcoholic steatohepatitis. Dig Dis Sci 2008; 53:1967-1976.
10. Park JW, Jeong G, Kim SJ, Kim MK, Park SM. Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J Gastroenterol Hepatol 2007; 22: 491-497.
11. Stranges S, Dorn JM, Muti P, et al. Body fat distribution, relative weight, and liver enzyme levels: a population- based study. Hepatology 2004;39:754-763.
12. André P, Balkau B, Vol S, Eschwège E; DESIR Study Group. Gamma-glutamyltransferase activity and development of the metabolic syndrome (International Diabetes Federation Definition) in middle-aged men and women: Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort. Diabetes Care 2007; 30:2355-2361.
13. Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity J Hepatol 2010 Nov 11.
14. Day CP, James OF. Steatohepatitis: a tale of two ''hits''? Gastroenterology 1998; 114:842-845.
15. Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28: 370-379.
16. Begriche, K. et al. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006; 6: 1-28.
17. Baskol G, Baskol M, Kocer D. Oxidative stress and antioxidant defenses in serum of patients withnon-alcoholic steatohepatitis. Clin Biochem 2007; 40:776-780.
18. Fierbinteanu Braticevici C, Mohora M., Cretoiu D, et al. Role of oxidative stress in the pathogenesis of chronic hepatitis C (CHC). Rom J Morphol Embryol 2009; 50:407-412.
19. Yoneda M, Mawatari H, Fujita K, et al. High sensitivity Creactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 2007;42:573-582.
20. Haukeland JW, Damas JK, Konopski Z, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006; 44:1167-1174.
21. Zimmermann E, Anty R, Tordjman J, et al. C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. J Hepatol 2011 Jan 13 (epub ahead of print)
22. Assy N, Schlesinger S, Hussein O. Elevated plasma protein C correlates with the presence of fatty liver. Gut 2005;54:729.
23. Malhi H, Kaufman RJ. Endoplasmic reticulum stress in liver disease. J Hepatol 2011; 54: 795-809.
24. Tarantino G, Pizza G, Colao A, et al. Hepatic steatosis in overweight/ obese females World J G astroenterol 2009; 15: 5693-5699.
25. Tarantino G, Conca P, Pasanisi F, et al. Could inflammatory markers help diagnose nonalcoholic steatohepatitis? Eur J Gastroenterol Hepatol 2009;21:504-511.
26. Pascale A, Pais R, Ratziu V. An overview of nonalcoholic steatohepatitis: past, present and future directions. J Gastrointestin Liver Dis 2010;19:415-423.
27. Bosy-Westphal A, Booke CA, Blöcker T, et al. Measurement site for waist circumference affects its accuracy as an index of visceral and abdominal subcutaneous fat in a Caucasian population. J Nutr 2010;140:954-961.
28. Adams LA, Angulo P. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis 2007;11:25-35.
29. Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008;48:792-798.
30. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-854.
31. Younossil ZM, Page S, Rafiq N, et al. A biomarker panel for nonalcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg 2011;21:431-439.
32. Lam KD, Bacchetti P, Abbasi F, et al. Comparison of surrogate and direct measurement of insulin resistance in chronic hepatitis C virus infection: impact of obesity and ethnicity. Hepatology 2010;52:38-46.